Literature DB >> 29496590

The immunopathogenesis of chronic and relapsing autoimmune uveitis - Lessons from experimental rat models.

Maria Diedrichs-Möhring1, Ulrike Kaufmann1, Gerhild Wildner2.   

Abstract

Autoimmune diseases usually follow a relapsing-remitting or a chronic progressive course. To understand the underlying immunopathogenesis we investigated experimental Lewis rat models displaying both disease types, which were only dependent on the autoantigen peptide used for immunization. Retinal S-Antigen-peptide PDSAg induces chronic, monophasic disease, whilst interphotoreceptor retinoid-binding protein (IRBP)-peptide R14 causes a spontaneously relapsing-remitting course. R14-mediated uveitis can be re-induced by immunization; PDSAg-induced disease is even preventable by prior CFA-injection. T cells with different antigen specificities preferentially infiltrate the eyes from different sites, e.g. choroid or retinal vessels, they remain in the retina after resolution of inflammation for many weeks. The major inflammatory cell populations in the eyes during rat uveitis are CD4+ or CD8+ monocytes/macrophages. Chemokine mutants only suppress PDSAg-mediated EAU, while IFN-α-treatment ameliorated R14-, but worsened PDSAg-induced disease. Comparison of T cells revealed upregulated expression of 26 genes related to various signal transduction pathways upstream and downstream of IFN-γ only in T cells causing relapsing EAU. Intraocular injection of IFN-γ induces synchronized relapses in R14-mediated uveitis, while VEGF-expression of PDSAg-specific T cells causing chronic disease induced chorioretinal neovascularization that is suppressed by anti-CD146 antibody. Intraocular T cells from rat eyes during EAU express IL-17, IFN-γ or IL-10, with dynamic changes of the cell populations during the disease course, differing in both disease types. Immunization of animals with a mixture of both antigens suppressed relapses, indicating a dominance of the monophasic disease. Understanding the exact pathogenesis of both disease courses is key to developing novel therapies for autoimmune diseases.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chemokines; Cytokines; Gene expression; Neovascularization; T cells; Uveitis

Mesh:

Substances:

Year:  2018        PMID: 29496590     DOI: 10.1016/j.preteyeres.2018.02.003

Source DB:  PubMed          Journal:  Prog Retin Eye Res        ISSN: 1350-9462            Impact factor:   21.198


  16 in total

Review 1.  Resolution of uveitis.

Authors:  Gerhild Wildner; Maria Diedrichs-Möhring
Journal:  Semin Immunopathol       Date:  2019-10-07       Impact factor: 9.623

2.  Lithocholic acid inhibits dendritic cell activation by reducing intracellular glutathione via TGR5 signaling.

Authors:  Jianping Hu; Yiting Zhang; Shenglan Yi; Chaokui Wang; Xinyue Huang; Su Pan; Jinglu Yang; Gangxiang Yuan; Sisi Tan; Hong Li
Journal:  Int J Biol Sci       Date:  2022-07-11       Impact factor: 10.750

Review 3.  Mesenchymal stromal cells for the treatment of ocular autoimmune diseases.

Authors:  Joo Youn Oh; Ryang Hwa Lee
Journal:  Prog Retin Eye Res       Date:  2021-03-26       Impact factor: 21.198

Review 4.  Visual Dysfunction in Multiple Sclerosis and its Animal Model, Experimental Autoimmune Encephalomyelitis: a Review.

Authors:  Taekyun Shin; Meejung Ahn; Jeongtae Kim; Kyungsook Jung; Changjong Moon; Moon-Doo Kim
Journal:  Mol Neurobiol       Date:  2021-03-20       Impact factor: 5.590

Review 5.  New Insights Into Immunological Therapy for Retinal Disorders.

Authors:  Atsunobu Takeda; Ryoji Yanai; Yusuke Murakami; Mitsuru Arima; Koh-Hei Sonoda
Journal:  Front Immunol       Date:  2020-07-03       Impact factor: 7.561

6.  PD-1+ melanocortin receptor dependent-Treg cells prevent autoimmune disease.

Authors:  Fauziyya Muhammad; Dawei Wang; Alyssa Montieth; Stacey Lee; Janine Preble; C Stephen Foster; Theresa A Larson; Kai Ding; Justin D Dvorak; Darren J Lee
Journal:  Sci Rep       Date:  2019-11-15       Impact factor: 4.379

Review 7.  Cytokines that Modulate the Differentiation of Th17 Cells in Autoimmune Uveitis.

Authors:  Kailei Guo; Xiaomin Zhang
Journal:  J Immunol Res       Date:  2021-03-16       Impact factor: 4.818

8.  Signature of Circulating Biomarkers in Recurrent Non-Infectious Anterior Uveitis. Immunomodulatory Effects of DHA-Triglyceride. A Pilot Study.

Authors:  Maria D Pinazo-Durán; Jose J García-Medina; Silvia M Sanz-González; Jose E O'Connor; Ricardo P Casaroli-Marano; Mar Valero-Velló; Maribel López-Gálvez; Cristina Peris-Martínez; Vicente Zanón-Moreno; Manuel Diaz-Llopis
Journal:  Diagnostics (Basel)       Date:  2021-04-19

Review 9.  Quantitative Assessment of Experimental Ocular Inflammatory Disease.

Authors:  Lydia J Bradley; Amy Ward; Madeleine C Y Hsue; Jian Liu; David A Copland; Andrew D Dick; Lindsay B Nicholson
Journal:  Front Immunol       Date:  2021-06-18       Impact factor: 7.561

Review 10.  Biotherapies in Uveitis.

Authors:  Mathilde Leclercq; Anne-Claire Desbois; Fanny Domont; Georgina Maalouf; Sara Touhami; Patrice Cacoub; Bahram Bodaghi; David Saadoun
Journal:  J Clin Med       Date:  2020-11-08       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.